Cassava Sciences Submits IND Application for Simufilam
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Cassava Sciences ( (SAVA) ).
Cassava Sciences has submitted an IND application to the FDA for a clinical trial of simufilam targeting TSC-related epilepsy. The FDA has requested additional information to assess risks and support the study, and Cassava plans to address these issues and initiate the trial in the first half of 2026.
The most recent analyst rating on (SAVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
Cassava Sciences faces significant financial challenges with no revenue and ongoing operational losses, reflected in the low financial performance score. Technical indicators show bearish trends, and the negative P/E ratio emphasizes valuation concerns. However, the strategic license agreement with Yale University could offer future growth potential, though it currently holds minimal weight due to its speculative nature.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences, Inc. operates in the pharmaceutical industry, focusing on developing innovative drugs for neurological conditions.
Average Trading Volume: 2,754,954
Technical Sentiment Signal: Sell
Current Market Cap: $146.4M
For detailed information about SAVA stock, go to TipRanks’ Stock Analysis page.
